Cingulate Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cingulate Inc. (CING) on July 2, 2026, covering events occurring on June 30, 2026, and July 2, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Kansas City, KS. Its common stock and warrants trade on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and regulatory disclosures rather than financial performance data.
Material Changes and Corporate Events
- Executive Employment Amendment: On June 30, 2026, Cingulate Therapeutics LLC, a wholly owned subsidiary, amended the Employment Agreement with Matthew N. Brams, Executive Vice President and Chief Medical Officer. The Trial Period for his full-time employment was extended from June 30, 2026, to September 30, 2026.
- Index Inclusion: On July 2, 2026, the Company announced its selection for membership in the Russell 3000 Index.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard disclosures associated with the employment amendment and index inclusion. The press release regarding the Russell 3000 Index is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the terms of the employment amendment for Matthew N. Brams in Exhibit 10.1 to confirm the duration and conditions of the extended trial period.
- Confirm the effective date of inclusion in the Russell 3000 Index via the press release in Exhibit 99.1.
- Note that the Company remains classified as an emerging growth company.